Quebec’s Conseil du Médicament, now the L’Institut national d’excellence en santé et en services sociaux (INESSS), reviewed long-acting generic medication Novo Methylphenidate ER-C under its mandate to promote clinical excellence and the efficient use of resources in the health and social services sector in Quebec.
While the Conseil recognises the therapeutic value of Nove Methylpenidate ER-C, and includes it in the List of Medications, it also believes « certain differences between these two products could result in clinical differences and a greater potential for illicit use ». An English translation in PDF format of the full French-language recommendation released in February 2011 is available here.